Mechanisms of sulindac-induced apoptosis and cell cycle arrest

Cancer Letters

Volumn 219, Issue 1, 2005, Pages 15-25

  Jung, Barbara ^a,b,c   Barbier, Valerie ^a   Brickner, Howard ^a   Welsh, John ^a   Fotedar, Arun ^a   McClelland, Michael ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Apoptosis; Cell cycle; Chemoprevention; Colon cancer; Sulindac

Indexed keywords

DRUG METABOLITE; FAS ANTIGEN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SULINDAC; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL LINE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; EMBRYO; EMBRYO CELL; FIBROBLAST; MAMMAL; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RETINOBLASTOMA; SIGNAL TRANSDUCTION; THYMOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROBLASTS; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; RETINOBLASTOMA PROTEIN; SULINDAC; T-LYMPHOCYTES;

MAMMALIA; MURINAE;

EID: 13444263535     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.06.015     Document Type: Article

References (53)

1. E. Giovannucci, E.B. Rimm, M.J. Stampfer, G.A. Colditz, A. Ascherio, and W.C. Willett Aspirin use and the risk for colorectal cancer and adenoma in male health professionals [see comments] Ann. Intern. Med. 121 1994 241 246
2. W.R. Waddell, and R.W. Loughry Sulindac for polyposis of the colon J. Surg. Oncol. 24 1983 83 87
3. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, and E. Kwong Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
4. D. Labayle, D. Fischer, P. Vielh, F. Drouhin, A. Pariente, and C. Bories Sulindac causes regression of rectal polyps in familial adenomatous polyposis Gastroenterology 101 1991 635 639
5. F.M. Giardiello, V.W. Yang, L.M. Hylind, A.J. Krush, G.M. Petersen, and J.D. Trimbath Primary chemoprevention of familial adenomatous polyposis with sulindac N. Engl. J. Med. 346 2002 1054 1059
6. R.S. Bresalier Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers Gastroenterology 123 2002 379 381
7. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
8. H. Sano, Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, and K. Asai Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Res. 55 1995 3785 3789
9. M. Tsujii, and R.N. DuBois Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 1995 493 501
10. G.A. Piazza, A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, and P.H. Gross Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis Cancer Res. 55 1995 3110 3116
11. G.A. Piazza, D.S. Alberts, L.J. Hixson, N.S. Paranka, H. Li, and T. Finn Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res. 57 1997 2909 2915
12. W. Sun, J.P. Stevenson, J.M. Gallo, M. Redlinger, D. Haller, and K. Algazy Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer Clin. Cancer Res. 8 2002 3100 3104
13. R. Hanif, A. Pittas, Y. Feng, M.I. Koutsos, L. Qiao, and L. Staiano-Coico Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochem. Pharmacol. 52 1996 237 245
14. X. Zhang, S.G. Morham, R. Langenbach, and D.A. Young Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts J. Exp. Med. 190 1999 451 459
15. M. Wick, G. Hurteau, C. Dessev, D. Chan, M.W. Geraci, and R.A. Winn Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth Mol. Pharmacol. 62 2002 1207 1214
16. R.E. Harris, S. Kasbari, and W.B. Farrar Prospective study of non-steroidal anti-inflammatory drugs and breast cancer Oncol. Rep. 6 1999 71 73
17. S.J. Shiff, L. Qiao, L.L. Tsai, and B. Rigas Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells J. Clin. Invest. 96 1995 491 503
18. E.K. Han, N. Arber, H. Yamamoto, J.T. Lim, T. Delohery, and R. Pamukcu Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines Breast Cancer Res. Treat. 48 1998 195 203
19. P.J. Pasricha, A. Bedi, K. O'Connor, A. Rashid, A.J. Akhtar, and M.L. Zahurak The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis Gastroenterology 109 1995 994 998
20. C. Martin, A. Connelly, T.O. Keku, S.B. Mountcastle, J. Galanko, and J.T. Woosley Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas Gastroenterology 123 2002 1770 1777
21. M. Gala, R. Sun, and V.W. Yang Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways Cancer Lett. 175 2002 89 94
22. C. Herrmann, C. Block, C. Geisen, K. Haas, C. Weber, and G. Winde Sulindac sulfide inhibits Ras signaling Oncogene 17 1998 1769 1776
23. T.C. He, T.A. Chan, B. Vogelstein, and K.W. Kinzler PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 99 1999 335 345
24. K.S. Berman, U.N. Verma, G. Harburg, J.D. Minna, M.H. Cobb, and R.B. Gaynor Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB Clin. Cancer Res. 8 2002 354 360
25. A.J. Wilson, A. Velcich, D. Arango, A.R. Kurland, S.M. Shenoy, and R.C. Pezo Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention Cancer Res. 62 2002 6006 6010
26. G.I. Evan, A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, and M. Brooks Induction of apoptosis in fibroblasts by c-myc protein Cell 69 1992 119 128
27. L. Tao, P.M. Kramer, W. Wang, S. Yang, R.A. Lubet, V.E. Steele, and M.A. Pereira Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents Carcinogenesis 23 2002 1447 1454
28. N.G. Nikitakis, A.W. Hamburger, and J.J. Sauk The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells Cancer Res. 62 2002 1004 1007
29. Y. Goldberg, I.I. Nassif, A. Pittas, L.L. Tsai, B.D. Dynlacht, B. Rigas, and S.J. Shiff The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins Oncogene 12 1996 893 901
30. V. Dulic, W.K. Kaufmann, S.J. Wilson, T.D. Tlsty, E. Lees, and J.W. Harper p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest Cell 76 1994 1013 1023
31. N. Dyson The regulation of E2F by pRB-family proteins Genes Dev. 12 1998 2245 2262
32. N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, and M.J. Kostura A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes Nature 356 1992 768 774
33. D.P. Lane Cancer. p53, guardian of the genome [news; comment] [see comments] Nature 358 1992 15 16
34. T. Hunter Oncoprotein networks Cell 88 1997 333 346
35. T. Miyashita, S. Kitada, S. Krajewski, W.A. Horne, D. Delia, and J.C. Reed Overexpression of the Bcl-2 protein increases the half-life of p21Bax J. Biol. Chem. 270 1995 26049 26052
36. Q. He, X. Luo, Y. Huang, and M.S. Sheikh Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells Oncogene 21 2002 6032 6040
37. X. Tang, Y.J. Sun, E. Half, M.T. Kuo, and F. Sinicrope Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells Cancer Res. 62 2002 4903 4908
38. R. Fotedar, H. Brickner, N. Saadatmandi, T. Rousselle, L. Diederich, and A. Munshi Effect of p21 waf1/cip1 transgene on radiation induced apoptosis in T cells Oncogene 18 1999 3652 3658
39. S. Kasibhatla, T. Brunner, L. Genestier, F. Echeverri, A. Mahboubi, and D.R. Green DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1 Mol. Cell 1 1998 543 551
40. C.M. Knudson, K.S. Tung, W.G. Tourtellotte, G.A. Brown, and S.J. Korsmeyer Bax-deficient mice with lymphoid hyperplasia and male germ cell death Science 270 1995 96 99
41. S.J. Martin, D.M. Finucane, G.P. Amarante-Mendes, G.A. O'Brien, and D.R. Green Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity J. Biol. Chem. 271 1996 28753 28756
42. A.R. Clarke, C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments] Nature 362 1993 849 852
43. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
44. T. Schmidt, K. Korner, H. Karsunky, S. Korsmeyer, R. Muller, and T. Moroy The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53 Cell Death Differ. 6 1999 873 882
45. S.J. Shiff, M.I. Koutsos, L. Qiao, and B. Rigas Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis Exp. Cell Res. 222 1996 179 188
46. J.A. Han, J.I. Kim, P.P. Ongusaha, D.H. Hwang, L.R. Ballou, and A. Mahale P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis Eur. Mol. Biol. Org. J. 21 2002 5635 5644
47. F. Paris, Z. Fuks, A. Kang, P. Capodieci, G. Juan, and D. Ehleiter Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293 297
48. S. Nagata Fas ligand-induced apoptosis Annu. Rev. Genet. 33 1999 29 55
49. L. Zhang, J. Yu, B.H. Park, K.W. Kinzler, and B. Vogelstein Role of BAX in the apoptotic response to anticancer agents [in process citation] Science 290 2000 989 992
50. Y. Sun, X.M. Tang, E. Half, M.T. Kuo, and F.A. Sinicrope Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells Cancer Res. 62 2002 6323 6328
51. R. Ravi, and A. Bedi Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L) Cancer Res. 62 2002 1583 1587
52. C.S. Williams, A.J. Watson, H. Sheng, R. Helou, J. Shao, and R.N. DuBois Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models Cancer Res. 60 2000 6045 6051
53. A.L. Hsu, T.T. Ching, D.S. Wang, X. Song, V.M. Rangnekar, and C.S. Chen The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J. Biol. Chem. 275 2000 11397 11403